Skip to main content
SpringerLink
Log in

A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients

  • Research Article
  • Published:
Tumor Biology

Abstract

Dendritic cells (DC) play a crucial role in the induction of an effective antitumor immune response. Cytokine-induced killer (CIK) cells, a subset of T lymphocytes, have the capacity to eliminate cancer cells. This study was to evaluate the correlation between the frequency of DC/CIK immunotherapies following regular chemotherapy, the time-to-progression (TTP), and overall survival (OS) of advanced non-small lung cancer patients. Sixty patients with IIIB–IV non-small-cell lung carcinoma (NSCLC) were enrolled from August 2007 to December 2009 and were randomized into two groups. All 60 patients received four courses of navelbine–platinum (NP) chemotherapy. In one group, 30 patients were treated with adoptive autologous DC/CIK cell transfusion twice every 30 days. In the other group, the patients received immunotherapies more than twice every 30 days. The adverse effects, TTP, and OS were evaluated between the two groups. Median survival time of all 60 patients was 13.80 months. The 1-, 2-, and 3-year overall survival rates were 60.0, 21.7, and 15.0 %, respectively. The 1-, 2-, and 3-year overall survival rates of patients receiving more than two immunotherapies were 63.3, 30.0, and 23.3 %, and the rates of those receiving two immunotherapies were 56.7, 13.3, and 6.7 %, respectively. The difference between the two groups was statistically significant (P = 0.037). Compared with patients in the fewer immunotherapies group, TTP in the group receiving more immunotherapies significantly prolonged, with the median improving from 6.2 months (95 % CI, 5.35–9.24) to 7.3 months (95 % CI, 5.45–6.95; P = 0.034). The adverse effects of chemoimmunotherapy were tolerable. Advanced NSCLC patients can benefit from the combination of DC/CIK immunotherapies following conventional chemotherapy. More than two immunotherapies improved TTP and OS of those patients in this study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010. doi:10.1016/j.ejca.2009.12.014.

    Google Scholar 

  2. Gadgeel SM. The optimal chemotherapy for stage III non-small cell lung cancer patients. Curr Oncol Rep. 2011. doi:10.1007/s11912-011-0170-3.

    PubMed  Google Scholar 

  3. Choudhury A, Palma M, Mellstedt H. The future of cancer vaccines for non-small-cell lung cancer: ongoing trials. Clin Lung Cancer. 2008. doi:10.3816/CLC.2008.s.006.

    PubMed  Google Scholar 

  4. Kelly RJ, Gulley JL, Giaccone G. Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer. 2010. doi:10.3816/CLC.2010.n.029.

    PubMed Central  PubMed  Google Scholar 

  5. Li H, Wang C, Yu J, Cao S, Wei F, Zhang W, et al. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy. 2009. doi:10.3109/14653240903121252.

    Google Scholar 

  6. Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgström P, et al. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer. 2005. doi:10.1002/ijc.21098.

    PubMed  Google Scholar 

  7. Tarassoff CP, Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer. Oncologist. 2006;11:5–451. doi:10.1634/theoncologist.

    Article  Google Scholar 

  8. Yang S, Tsang KY, Schlom J. Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells. Clin Cancer Res. 2005. doi:10.1158/1078-0432.CCR-05-0670. 10.1158%2F1078-0432.CCR-05-0670#pmc_ext.

    PubMed Central  Google Scholar 

  9. Margolin KA, Negrin RS, Wong KK, Chatterjee S, Wright C, Forman SJ. Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev. 1997. doi:10.1111/j.1600-065X.1997.tb00986.x.

    PubMed  Google Scholar 

  10. Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother. 2001. doi:10.1097/00002371-200111000-00007.

    PubMed  Google Scholar 

  11. Kalady MF, Onaitis MW, Emani S, Abdel-Wahab Z, Tyler DS, Pruitt SK. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. J Surg Res. 2004. doi:10.1016/j.jss.2003.09.003.

    PubMed  Google Scholar 

  12. Yang L, Ren B, Li H, Yu J, Cao S, Hao X, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother. 2013. doi:10.1007/s00262-012-1311-8.

    Google Scholar 

  13. Zhong R, Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother. 2011. doi:10.1007/s00262-011-1060-0.

    PubMed  Google Scholar 

  14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000. doi:10.1093/jnci/92.3.205. 10.1093%2Fjnci%2F92.3.205.

    PubMed  Google Scholar 

  15. Nencioni A, Brossart P. Cellular immunotherapy with dendritic cells in cancer: current status. Stem Cells. 2004. doi:10.1634/stemcells.22-4-501.

    PubMed  Google Scholar 

  16. Aloysius MM, Mc Kechnie AJ, Robins RA, Verma C, Eremin JM, Farzaneh F, et al. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. J Transl Med. 2009. doi:10.1186/1479-5876-7-18.

    PubMed Central  PubMed  Google Scholar 

  17. Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol. 2011. doi:10.1016/j.jhep.2010.12.031.

    PubMed  Google Scholar 

  18. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005. doi:10.1016/j.bbmt.2004.11.019.

    PubMed  Google Scholar 

  19. Yanagimoto H, Takai S, Satoi S, Toyokawa H, Takahashi K, Terakawa N, et al. Impaired function of circulating dendritic cells in patients with pancreatic cancer. Clin Immunol. 2005. doi:10.1016/j.clim.2004.09.007.

    PubMed  Google Scholar 

  20. Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 2009. doi:10.1158/0008-5472.CAN-09-1106.

    Google Scholar 

Download references

Acknowledgments

This study was supported by Nature Science Foundation of China (number: 81101722 and 81201770). The authors would like to thank Huifang Sha for excellent technical support and Weiming Mao for critically reviewing the manuscript.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Pulmonary Disease, Shanghai Chest Hospital, Shanghai Jiao Tong University, No. 241, Huaihai Road (W), Shanghai, People’s Republic of China

    Runbo Zhong, Baohui Han & Hua Zhong

Authors
  1. Runbo Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baohui Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hua Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hua Zhong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhong, R., Han, B. & Zhong, H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumor Biol. 35, 987–994 (2014). https://doi.org/10.1007/s13277-013-1132-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-1132-1

Keywords

Search

Navigation